A new discovery in the diabetes field reveals how useful glycated albumin (GA) can be as a glycemic indicator for people on peritoneal dialysis (PD). It is already known that GA surpasses HbA1c in accurately estimating glycemic control in hemodialysis patients with diabetes. A study done by Kobayashi et al (2016) discovered that compared to HbA1c, GA can be a more useful marker for the assessment of glycemic control in diabetic patients on peritoneal dialysis (PD). This was an unexpected discovery since hypoalbuminemia is common in PD patients which led researchers to hypothesize that GA levels would be underestimated. However, this study showed that albumin levels didn’t affect GA levels in PD patients. In fact, GA was found as the only independent factor affecting glucose levels for diabetic patients on PD. Although more research is anticipated to better understand this peculiar relationship, nevertheless these findings reveal versatility of GA as a surrogate glycemic marker.
Citation: Kobayashi, Hiroki, Masanori Abe, Yoshinori Yoshida, Hiroko Suzuki, Noriaki Maruyama, and Kazuyoshi Okada. "Glycated Albumin versus Glycated Hemoglobin as a Glycemic Indicator in Diabetic Patients on Peritoneal Dialysis." IJMS International Journal of Molecular Sciences 17.5 (2016): 619. Web.
Other sources- http://www.epinexdiabetesblog.com/#!Glycated-Albumin-The-Next-A1c/cjds/563a6a670cf28330832d23be